Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-11-29
2003-06-17
Fonda, Kathleen K. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S021000
Reexamination Certificate
active
06579858
ABSTRACT:
The present invention relates to the use of low-molecular-weight heparins for the prevention and treatment of cerebral edemas.
The invention also relates to the use of low-molecular-weight heparins for the preparation of a medicament for the prevention and treatment of cerebral edemas.
Standard heparin is a sulphated polysaccharide having an average molecular weight of 12,000-15,000 daltons which is isolated from bovine, ovine and porcine intestinal mucous membranes. Heparin is clinically used for the prevention and treatment of thromboembolic disorders but sometimes causes haemorrhages.
Over the past ten years, heparin has been gradually replaced by low-molecular-weight heparins which no longer exhibit or which exhibit to a lesser degree the disadvantage of causing bleeding and which now require only one injection per day instead of 2 to 3 injections per day for standard heparin. These low-molecular-weight heparins are prepared in particular by fractionation, controlled depolymerization of heparin or by chemical synthesis. They have an anti-Xa activity/anti-IIa activity ratio greater than 2.
It has now been found that low-molecular-weight heparins reduce cerebral edemas.
Cerebral edemas represent a major aggravating consequence of thromboembolic cerebrovascular accidents, of cerebral haemorrhages and of traumas of the central nervous system (cerebral trauma or medullary trauma) but also of cardiac and/or respiratory arrests, or any functionally equivalent situation regardless of its origin (ventricular fibrillation, malignant asthma attack). Cerebral edemas can also be found in any pathological or accidental situation of coma accompanied by hypoperfusion of the cerebral parenchyma. Cerebral edemas may also accompany cerebral tumours, irradiations and bacterial, viral and parasitic infections of the cerebral parenchyma.
REFERENCES:
patent: 2013092 (1994-05-01), None
Pratt et al.HaemostasisMar.-Apr. 1998, 28(2), 78-85.*
Physician' s Desk Reference, 1995, 49th Edition, Medical Economics Data Production Company, Montvale, New Jersey, pp. 1968-1969.*
Bes, et al., “Medical Therapeutic Strategy of Acute Cerebral Ischaemia in Adults,”J. Neuroradiol, 20, 102-120 (1993).
Van Gijn, “Thrombolysis in Ischemic Stroke: Double or Quits?.” Circulation, 93, 1616-17 (1996).
Marx, “Die Therapie des Akuten Ischamischen Insultes,” Hamostaseologie, 17, 86-91 (1997). In German.
Fareed et al., “Comparative Study on the in vitro and in vivo Activities of Seven Low-Molecular-Weight Heparius,” Haemostasis, 18 (suppl. 3), 3-15 (1988).
Fujii et al., “Treatment for Delayed Brain Injury After Pituitary Irradiation,” Neurol. Surg., 16(3), 241-247 (1988). (English-language Abstract Only).
Green et al., “Prevention of Thromboembolism after Spinal Cord Injury Using Low-Molecular-Weight Heparin,” Annal. Intern. Med., 113, 571-574 (1990).
Kay et al., “Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke,” New Eng. J. Med., 333(24), 1588-1593 (1995).
DiStefano et al., “Low-Molecular-Weight Heparins for Long-Term Therapy of Peripheral Vascular Disease,” Therapeut, Res., 44(1), 1-9 (1988).
Tzonos et al., “The Effect of Proteinasen and Fibrinolysis Inhibitors on Experimental Brain Edemo,” Z. Neurol., 205(1), 61-70 (1973). (English language abstract only).
Mary Véronique
Pratt Jeremy
Stutzman Jean-Marie
Uzan Andre
Wahl Florence
Aventis Pharma S.A.
Fonda Kathleen K.
Newman Irving
LandOfFree
Use of low-molecular-weight heparins for the prevention and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of low-molecular-weight heparins for the prevention and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of low-molecular-weight heparins for the prevention and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3134425